Investigational amylin analogue

Cagrilintide

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

Investigational and not FDA-approved; FDA says it has not been found safe and effective for any condition and cannot lawfully be used in compounding.

Category: Investigational amylin analogue
Routes represented: Subcutaneous (SubQ)
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Authoritative overview

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: nausea, constipation, diarrhea, injection-site reactions.

Investigational; long-term and rare adverse effects are not established.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With Pramlintide

Safety flag

Additive gastric-emptying delay, GI intolerance, and glucose lowering are plausible; a broad clinical contraindication is not established.

Interaction evidence source

With semaglutide

Complementary evidenceLv3

Randomized human trials directly studied co-administered cagrilintide and semaglutide and found complementary weight and glycemic effects.

Interaction evidence sourcePhase 3 trialFDA unapproved GLP-1 warning

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.